Ligand Pharmaceuticals Incorporated acquires Pfenex Inc. (2020)

Deal facts

Buyer: Ligand Pharmaceuticals Incorporated
Target: Pfenex Inc.
Deal value: Not disclosed
Announced: 10 August 2020
Status: Completed
Sector: Healthcare
Country: United States
Consideration: cash, earn-out

Sources

SEC_EDGAR_8K

What we know

More M&A Tools

Explore the Toolkit

Tools, frameworks and AI assistants designed for entrepreneurs serious about M&A.

Access now

Deal timeline

1 update

1 Oct 2020CompletedClosed
Ligand Pharmaceuticals Incorporated completes acquisition of Pfenex Inc.
Item 2.01 Completion of Acquisition or Disposition of Assets. On October 1, 2020, Ligand Pharmaceuticals Incorporated, a Delaware corporation (“Ligand”), completed the previously announced acquisition of Pfenex Inc., a Delaware corporation (“Pfenex”), pursuant to the Agreement and Plan of Merger (the “Merger Agreement”), dated as of August 10, 2020, by and among Ligand, Pfenex and Pelican Acquisit
Source

OpinionExit Mode editorial

We see a clear signal in the transaction where Ligand Pharmaceuticals Incorporated acquired Pfenex Inc. to take the target private. Announced on 10 August 2020, this deal moved a US healthcare firm from public markets into private ownership. The structure relies on a mix of cash and an earn-out. This specific combination often reflects a buyer who wants immediate control but needs the seller to prove future performance before releasing the full price. It is a common mechanic when the acquirer sees value that the market currently underestimates but requires validation over time.

For the SME founder reading this, the choice of an earn-out introduces a distinct commercial risk. It shifts the burden of value creation onto the post-close period. If the business does not hit the agreed targets, the final consideration drops. This is not merely a pricing detail; it is a change-of-control covenant that dictates your operational freedom for years. In the healthcare sector, where regulatory timelines and clinical outcomes drive value, tying a portion of the sale to future milestones can be precarious. The buyer assumes the asset, yet the seller remains financially exposed until the earn-out conditions are satisfied.

The going-private nature of this deal also suggests a desire to escape the short-term pressures of public reporting. Ligand likely sought the flexibility to restructure or integrate Pfenex without quarterly scrutiny. While this offers strategic breathing room, it removes the liquidity event that many founders expect. The deal status is now completed, meaning the terms were accepted and the transition executed. This outcome highlights that even in a sector as stable as healthcare, the path to exit often involves trade-offs between immediate cash and future potential.

You must scrutinise the earn-out triggers in your own data room this week. Do not accept vague language regarding performance metrics. Define the specific clinical or commercial milestones that unlock the deferred payment and ensure they are within your team's direct control. If the targets rely on external regulatory approvals or market shifts you cannot influence, the deal value is illusory. Demand clarity on the measurement period and the dispute resolution mechanism before signing.

Editorial opinion. Not financial or legal advice.

Explore

Browse adjacent archives

Jump from this deal into the sector, buyer, deal type, and year views that carry the strongest contextual signal.

More Healthcare deals More 2020 deals More going private deals More from Ligand Pharmaceuticals Incorporated All M&A deals

Similar deals

Other Healthcare M&A activity tracked by Exit Mode.

6 July 2026CompletedHealthcare

Trafalgar Asset Management, LLC to acquire The Greater Cannabis Company, Inc.

Trafalgar Asset Management, LLC has agreed to acquire The Greater Cannabis Company, Inc. in a going private transaction. The deal was announced on 6 July 2026, following…

Buyer: Trafalgar Asset Management, LLC
Target: The Greater Cannabis Company, Inc.
Deal value: Not disclosed
Deal type: going private

Read deal Healthcare deals going private deals United States deals

30 June 2026CompletedHealthcare

Hanmi Pharmaceuticals Co. Ltd. to acquire Aptose Biosciences Inc.

Hanmi Pharmaceuticals Co. Ltd. has agreed to acquire Aptose Biosciences Inc. in a going private transaction valued at USD 3,466,470. The consideration for this deal cons…

Buyer: Hanmi Pharmaceuticals Co. Ltd.
Target: Aptose Biosciences Inc.
Deal value: USD 3,466,470
Deal type: going private

Read deal Healthcare deals going private deals Canada deals

9 June 2026CompletedHealthcare

GlaxoSmithKline LLC to acquire Nuvalent, Inc.

GlaxoSmithKline LLC has agreed to acquire Nuvalent, Inc. in a going private transaction. The deal was announced on 9 June 2026 and completed on 15 July 2026. The conside…

Buyer: GlaxoSmithKline LLC
Target: Nuvalent, Inc.
Deal value: Not disclosed
Deal type: going private

Read deal Healthcare deals going private deals United States deals

3 June 2026CompletedHealthcare

FONAR, LLC to acquire FONAR Corporation

FONAR, LLC has agreed to acquire FONAR Corporation in a going private transaction completed on 3 June 2026. The deal involves the purchase of the US-based healthcare com…

Buyer: FONAR, LLC
Target: FONAR Corporation
Deal value: Not disclosed
Deal type: going private

Read deal Healthcare deals going private deals United States deals

13 May 2026CompletedHealthcare

Zydus Worldwide DMCC to acquire Assertio Holdings, Inc.

Zydus Worldwide DMCC has agreed to acquire Assertio Holdings, Inc. in a going private transaction valued at an undisclosed amount. The deal, announced on 13 May 2026, wa…

Buyer: Zydus Worldwide DMCC
Target: Assertio Holdings, Inc.
Deal value: Not disclosed
Deal type: going private

Read deal Healthcare deals going private deals United States deals

Buyer history